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Dasatinib was approved at 100 mg once daily for imatinib-resistant or -intolerant patients with chronic
myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180-034 (NCT00123474) study.
Here we present the final 7-year analysis of this pivotal study, the longest follow-up to date of any second-
generation BCR–ABL1 tyrosine kinase inhibitor (TKI). Patients (n 5 670) with imatinib-resistant or -intolerant
CML in chronic phase received dasatinib. Nineteen percent of patients continued on study treatment, with a
greater proportion in the 100 mg once daily arm remaining on therapy. Seven-year rates for major molecular
response (MMR), progression-free survival (PFS), and overall survival (OS) were similar across doses; MMR,
PFS, and OS results were 46, 42, and 65% at 100 mg once daily, respectively. Improved PFS and OS rates
were reported in patients who achieved BCR–ABL1 10% at 3 and 6 months. No new safety signals were
identified. The incidence of drug-related pleural effusion was 28% at 100 mg once daily and 35% at the
other three dose groups. Incidence of drug-related pulmonary hypertension and pulmonary arterial
hypertension remained low (3% across all doses). Arterial ischemic events occurred in 4% of patients
across all doses. These data support the long-term efficacy and well-established safety profile of
dasatinib for patients with imatinib-resistant or -intolerant CML in chronic phase.
Am. J. Hematol. 91:869–874, 2016. VC 2016 The Authors. American Journal of Hematology Published by Wiley Periodicals, Inc.
 Introduction
The introduction of BCR–ABL1 tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) resulted in improved
patient prognosis, including greater survival rates, compared with the two previous standards of care [1–3]. Survival in CML patients is now nearly
identical to that of the general population [4]. CML is currently considered a manageable chronic disease, requiring many patients to remain on
TKI therapy indefinitely. Given the long-term nature of treatment for CML, monitoring patients as they continue therapy is valuable for under-
standing the durability of responses, and for recognizing the emergence of new or previously unrecognized adverse events (AEs).
Dasatinib, a second-generation TKI active against ABL, PDGFRb, KIT, and SRC family kinases, is approved for the treatment of newly diag-
nosed adults with Ph1 CML in chronic phase (CP); adults with Ph1 CML in chronic phase, accelerated phase (AP), or blast phase (BP) with
resistance or intolerance to prior therapy including imatinib; and for adults with Ph1 acute lymphoblastic leukemia who have become resistant to
or intolerant of other treatment [5]. Previous analysis from the initial report at 6-month follow-up for the phase 3 CA180-034 dose-optimization
study in imatinib-resistant or -intolerant CML-CP patients showed similar dasatinib efficacy with all dosing regimens evaluated; however, the
100 mg once-daily (QD) dosing schedule showed improved tolerability with a reduced incidence of treatment-related AEs of interest (i.e., pleural
effusion and cytopenia), leading to a label change as the recommended dasatinib dose regimen in this patient population [5,6]. Longer-term fol-
low-up of patients in this trial at 6 years continued to demonstrate durable efficacy and safety with dasatinib at 100 mg QD [1]. Here, we report
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the final 7-year analysis of efficacy and safety outcomes of CA180-
034, which represents the longest follow-up to date in the second-line
of any second-generation BCR–ABL1 TKI.
 Methods
Detailed methods have been previously reported and are outlined in Supporting
Information Materials. CA180-034 (NCT00123474), a randomized phase 3 study, com-
pared the dose and schedule of dasatinib therapy for optimal benefit/risk ratio among
patients with imatinib-resistant or -intolerant CML-CP. The primary objective of this
study was to compare the major cytogenetic response (MCyR) rates of dasatinib after a
minimum follow-up of 6 months when administered QD with dasatinib administered
twice daily (BID). Secondary end points included other efficacy and safety assessments.
Patient eligibility criteria were previously described [6]. Patients were stratified
by imatinib resistance or intolerance. The study was conducted in accordance with
the Declaration of Helsinki and was approved by local ethics committees. Written
informed consent was obtained from each patient before participation.
Eligible patients were randomized 1:1:1:1 to receive dasatinib 100 mg QD,
50 mg BID, 140 mg QD, or 70 mg BID. To manage inadequate responses or AEs,
dose escalation (up to a total daily dose [TDD] of 180 mg) and dose interruption
or reduction (down to a TDD of 20 mg) were allowed. After 2 years, the protocol
was amended to allow switching from a BID to a QD regimen, at the same TDD, if
the patient experienced a recurrence of anemia, thrombocytopenia, neutropenia,
pleural effusion, or any other fluid retention during study progress following at
least one dose reduction, at the investigator’s discretion [1]. Treatment was admin-
istered until protocol-defined disease progression or death, unacceptable toxicity, or
patient/investigator request.
Figure 1. Kaplan–Meier analyses. All subjects included in these analyses were randomized. Rates for PFS and OS at 7 years from randomization were com-
parable across treatment arms. Panel A: progression-free survival (PFS), Panel B: overall survival (OS).
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Efficacy and safety assessments were collected for the intent-to-treat population
as described in earlier reports [1,6]; they were assessed and are reported by
randomized arm, with the exception of landmark analyses.
Major molecular response (MMR) was defined as BCR–ABL1 transcript level
0.1% on the International Scale (IS), molecular response (MR4) was defined as
BCR–ABL1 transcript level (IS) 0.01%; MR4.5 was defined as a BCR–ABL1 (IS)
transcript level 0.0032%.
For this study, progression was defined as increasing white blood cell (WBC)
count, loss of complete hematologic response (CHR) or MCyR, 30% increase in
Ph1 metaphases, or transformation to AP or BP disease [6]. OS was defined as time
from randomization until death. Survival data for all patients was collected for up to
7 years, including those who discontinued dasatinib treatment earlier. Reason for pro-
gression was captured for patients who progressed during treatment, but only the date
of progression was captured for events occurring after treatment ended. Patients who
survived or who were lost to follow-up were censored on the last date the patient was
known to be alive. Mutational analyses were conducted as described previously [6,7].
BCR–ABL1 mutations were assessed in patients prior to the start of dasatinib and at
time of progression or end of treatment. Safety analyses included all patients who
received at least one dose of dasatinib. AEs are reported as cumulative incidence,
unless otherwise noted. AEs during the 7-year follow-up were graded based on the
National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 [8].
No formal statistical comparisons were conducted for the 7-year analysis. PFS,
OS, and the landmark analyses were estimated using Kaplan–Meier product-limit
methodology [1]. P values were not adjusted for multiple comparisons; secondary
analyses are thus descriptive.
 Results
Patient disposition
Of 670 randomized patients, 662 were treated across 138 sites
globally (Supporting Information Fig. 1) [1,6,7]. Patient demographics
and baseline characteristics were well balanced among treatment arms
(Supporting Information Table I). Across dose groups, the majority
of patients (74%) had imatinib resistance. Approximately 41% of
patients received prior imatinib therapy for >3 years. Other prior
therapies included interferon-a (52%), chemotherapy (26%), and allo-
geneic stem cell transplantation (5%). The following data are reported
according to a database lock at approximately 84 months.
With 7 years of follow-up, the overall median duration of therapy
was the longest in the 100 mg QD arm at 37 months (50 mg BID:
28 months, 140 mg QD: 27 months, and 70 mg BID: 29 months).
Thirty-eight percent of patients in the 100 mg QD arm maintained
their assigned dose, compared with those in the other arms (50 mg
BID: 19%, 140 mg QD: 24%, and 70 mg BID: 9%). After 2 years, the
protocol was amended to allow switching from BID to QD dosing;
54.8% of those in the 50 mg BID arm and 50.5% of those in the 70 mg
BID arm still on treatment switched to the QD dosing schedule. All
data included are reported by randomized arm. Twenty-two percent of
patients in the 100 mg QD arm remained on dasatinib treatment for at
least 7 years, compared with 19% in the 50 mg BID arm, 15% in the
140 mg QD arm, and 19% in the 70 mg BID arm. The most common
reason for discontinuation was “other,” as a majority of these patients
moved off-study and on to commercial supply of dasatinib. Other rea-
sons for discontinuation were drug-related AEs (100 mg QD: 24%,
50 mg BID: 27%, 140 mg QD: 28%, and 70 mg BID: 31%; all percen-
tages given are out of total patients treated; Supporting Information
Table II) or protocol-defined progression (100 mg QD: 21%, 50 mg
BID: 17%, 140 mg QD: 26%, and 70 mg BID: 16%; all percentages
given are out of total patients treated; Supporting Information Table II).
Efficacy: molecular responses, PFS, and OS
During the 7-year follow-up, 94% of patients (n 5 624) were evaluable
for the achievement of MMR. Best on-study rates for MMR (reported as a
percentage of number of responders divided by assessed treated patients)
were similar across dose groups at 46, 44, 44, and 46%, in the 100 mg QD,
50 mg BID, 140 mg QD, and 70 mg BID arms, respectively. MMR rates at
7 years among all randomized patients were comparable at 13, 10, 11, and
14%, respectively, in the four treatment arms. Rates for MR4 and MR4.5 at
any time, which were evaluated in all randomized patients, were greatest
in the 100 mg QD arm at 29 and 20%, respectively, compared with each
of the other arms (50 mg BID: 21 and 13%; 140 mg QD: 23 and 11%;
70 mg BID: 22 and 14%, respectively). Rates for PFS and OS at 7 years
from randomization were comparable across treatment arms (Fig. 1).
Subgroup analyses showed that MMR rates were comparable in
imatinib-resistant patients across dose groups (Table I). For imatinib-
intolerant patients, MMR was 75% in the 140 mg QD arm, 55% in the
100 mg QD arm, 59% in the 50 mg BID arm, and 57% in the 70 mg
QD arm. For imatinib-resistant patients, OS and PFS rates were similar
across the dose groups with overlapping 95% CIs, which was also a
trend in the imatinib-intolerant subgroup and in the overall population.
A landmark analysis conducted in patients in the dasatinib 100 mg
QD arm who achieved BCR–ABL1 (IS) 10% at 3 and 6 months dem-
onstrated improved PFS and OS compared with patients with BCR–
ABL1 (IS) >10% (Supporting Information Table III; Fig. 2). Seven-year
OS rates for patients with BCR–ABL1 (IS) 10% at 3 and 6 months
were 72 and 74%, respectively; for patients with BCR–ABL1 (IS) >10%
at 3 and 6 months they were 56 and 50%, respectively (Supporting
Information Table III). Seven-year PFS rates for patients with BCR–
ABL1 (IS) 10% at 3 and 6 months were 56 and 57%, respectively; for
patients with BCR–ABL1 (IS) >10% at 3 and 6 months they were 21
and 4%, respectively (Supporting Information Table III).
 Mutational analysis
BCR–ABL1 kinase domain mutations were assessed in all patients at
baseline and at the end of treatment. The majority of patients who dis-
continued because of loss of response did not have a BCR–ABL1 muta-
tion at baseline (n 5 72) or at end of treatment (n 5 71), as shown in
Supporting Information Table IV. Of those with mutations, the three
most common that emerged while on dasatinib were V299L (n 5 10),
T315I (n 5 19), and F317L (n 5 12), each a known dasatinib-resistant
mutation. Furthermore, two of these mutations were detected both at
baseline and at the end of study (T315I [n 5 9], F317L [n 5 3]); selec-
ted mutations characterized as dasatinib-sensitive were lost during the
TABLE I. Subgroup Analyses for Efficacy: MMR, PFS, and OS
Dasatinib treatment arms
100 mg QD (n 5 167) 50 mg BID (n 5 168) 140 mg QD (n 5 167) 70 mg BID (n 5 168)
Imatinib status
Resistant
(n 5 124)
Intolerant
(n 5 43)
Resistant
(n 5 124)
Intolerant
(n 5 44)
Resistant
(n 5 123)
Intolerant
(n 5 44)
Resistant
(n 5 126)
Intolerant
(n 5 42)
MMR in assessed
treated patients, n (%)
51 (43) 22 (55) 46 (39) 24 (59) 38 (34) 30 (75) 48 (42) 21 (57)
PFS, % (95% CI) 39 (29–49) 51 (32–67) 42 (32–52) 48 (27–65) 30 (21–40) 67 (46–81) 41 (31–51) 50 (30–67)
OS, % (95% CI) 63 (53–71) 70 (52–82) 68 (58–76) 77 (60–87) 68 (58–76) 88 (72–95) 65 (55–73) 78 (60–88)
BID, twice daily; MMR, major molecular response; OS, overall survival; PFS, progression-free survival; QD, once daily.
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course of treatment (total number in brackets 5 retained 1 emerged;
T315I [n 5 28], and F317L [n 5 15]; Supporting Information Table IV).
 Safety
Most patients (99%) participating in this study experienced at least
one AE, with the majority considered drug-related AEs (94%) by the
investigators. Severe (grade 3) drug-related AEs were reported in 53%
of treated patients, and in a lower proportion of patients in the 100 mg
QD arm than the other treatment arms (45 vs. 56%, respectively).
A total of 184 deaths (28%) were reported, with similar percen-
tages in the 100 mg QD arm (31%) and the other arms (27%). The
most common cause of death was disease related (17% in the 100 mg
QD arm and 11% in the other arms). There were three deaths (<1%)
attributed to study-drug toxicity across all arms (one due to sepsis; one
due to necrosis of the colon; and one in a patient with pulmonary
edema, congestive heart failure, neck pain, and pleural effusion). Across
all study arms, 22 (3%) patients died due to infection; the most com-
mon types leading to death were sepsis (9) and pneumonia (8); 19 of
the 22 patients who died due to infection had discontinued dasatinib
more than 30 days before death. There were no new deaths due to
study drug toxicity reported since the 6-year follow-up report [1].
Most AEs (all grades) first occurred within 24 months of treatment and
were primarily mild to moderate (grade 1/2). At 7 years, cumulative rates of
AEs of special interest (regardless of relationship to study drug; all grades)
for the 100 mg QD arm compared with the other treatment arms were:
hemorrhage (26 vs. 28%), pleural effusion (27 vs. 36%), diarrhea (42 vs.
47%), nausea/vomiting (27 vs. 43%), fatigue (37 vs. 34%), myalgias/arthral-
gias (38 vs. 33%), and rash (33 vs. 36%; Supporting Information Table V).
First occurrences of pleural effusion (regardless of relationship to
study therapy; any grade) were reported in 34%, with a minority
(8%) experiencing severe pleural effusion (100 mg QD: any grade
Figure 2. Kaplan–Meier landmark analyses at 3 months for 100 mg QD. All subjects included in these analyses were randomized. The analyses show
improved PFS and OS compared with patients with BCR–ABL1 >10%. Panel A: progression-free survival (PFS), Panel B: overall survival (OS).
Shah et al. RESEARCH ARTICLE
872 American Journal of Hematology, Vol. 91, No. 9, September 2016 doi:10.1002/ajh.24423
[grades 3/4], 28% [5%] vs. other treatment arms: any grade [grades 3/4],
36% [9%]). No deaths due to pleural effusion events were reported. In
year 7 of the study, new cases of pleural effusion (regardless of relation-
ship to study therapy) occurred in 5% (2/42) of patients at risk treated
in the 100 mg QD arm compared with 8% (7/88) in the other treatment
arms. Half the pleural effusion events (23/46 cases; Table II) occurred
within the first 2 years of treatment among patients in the 100 mg QD
arm. Drug-related pleural effusion was reported at a rate of 28% in the
100 mg QD arm vs. 35% in the other dose groups (Table II). Pleural
effusion cases leading to treatment discontinuation were all considered
drug-related; 7% of patients with pleural effusion in the 100 mg QD
arm discontinued therapy (2% grade 3/4) vs. 11% (3% grade 3/4) in the
other dose groups.
Pulmonary hypertension (PH), or pulmonary arterial hypertension
(PAH), were reported on the basis of diagnostic evaluations including
echocardiogram, chest X-ray, cardiac catheterization, and blood tests.
PH of any grade was reported in 16 patients (2.4%) with seven (1.1%)
experiencing a grade 3/4 event (100 mg QD: any grade [grades 3/4],
three patients (1.8%) [two patients (1.2%)] vs. other treatment arms:
any grade [grades 3/4], 3% [1%]). PAH confirmed by right-heart cathe-
terization was reported in one patient in the 100 mg QD group (at
75 months). Cumulative rates of PH and PAH over time are shown in
Table II.
Incidence of arterial ischemic events (all grades) was low overall in
the study. Cardiovascular ischemic events (defined as myocardial
infarction, angina pectoris, or coronary artery disease) were reported
in 4% of patients in the 100 mg QD arm and 4% in the other dose
groups. The specific cardiac ischemic events reported in the 100 mg
QD arm and the other dose groups were myocardial infarction (2 vs.
1%, respectively), angina pectoris (1 vs. 2%, respectively), and coro-
nary artery disease (1 vs. <1%, respectively). The majority of cardiac
ischemic events were grades 3/4 (2 vs. 2%, respectively); additionally,
one patient (<1%) in the other dose groups experienced a fatal grade
5 myocardial infarction. Peripheral vascular events (all grades) were
reported in 1% of patients in the other dose groups (no events in the
100 mg QD arm), with <1% reported as grades 3/4. Cerebrovascular
events (all grades) were reported in 3 and 1% of patients in the
100 mg QD and other dose groups, respectively. In the 100 mg QD
arm, 1% of cerebrovascular events were grades 3/4; all events in the
other dose groups were grades 3/4. There were no reports of stroke.
Over the 7-year course of the study, 66% of all treated patients
experienced infections (any cause, all grades); 67% of patients in the
100 mg QD arm and 65% of patients in the other dose arms experi-
enced infections (Supporting Information Table VI). In the 100 mg
QD arm, 53% of patients had on-study worst grade 1/2 infections, and
13% had worst grade events of 3 or 4; across the other arms, 49% of
patients had on-study worst grade 1/2 infections and 15% had a worst
grade 3/4 infection. Among the two patients in the 100 mg QD arm
who had an on-study worst grade infection of 5, one was a lung infec-
tion and one was due to septic shock. In the other arms, three patients
had an on-study worst grade 5 infection, one from pneumonia, and
two from skin infections. The majority of infectious deaths occurred
after dasatinib treatment was discontinued (range, 1 day–16 months).
Neutropenia was not associated with infections among patients who
received dasatinib. The majority of infections resolved.
 Discussion
At 7 years of follow-up, this analysis of dasatinib treatment from
the CA180-034 dose optimization trial represents the longest follow-
up of a second-generation BCR–ABL1 TKI in the second line. Con-
sistent with previous reports, dasatinib treatment at a dose of 100 mg
QD demonstrated durable efficacy and a tolerable long-term safety
profile in imatinib-resistant and -intolerant CML-CP patients.
With the advent of BCR–ABL1 TKIs, CML is currently considered a
chronic condition, in which most patients are able to achieve long-
term survival [1–3]. Initial and continuing monitoring of responses is
critical to ensure optimal management of CML, since early responses
are predictive of long-term outcomes [9–13]. Furthermore, prompt
identification of patients who are resistant or intolerant to their first-
line therapy is imperative, so that they may be switched early to a
second-line TKI and potentially improve long-term outcomes [12–14].
In this analysis, we report that 19% of extensively pretreated patients
continued dasatinib on study for at least 7 years, with a greater propor-
tion of patients in the 100 mg QD arm remaining on treatment
(median duration, 37 months). Dasatinib at 100 mg QD was better tol-
erated than other dosing regimens: more patients in this group main-
tained their assigned dose (38%) compared with the other treatment
groups (50 mg BID: 19%, 140 mg QD: 24%, and 70 mg BID: 9%).
With a minimum follow-up of 7 years, treatment with dasatinib at
100 mg QD continues to provide efficacy similar to the initially
approved dose of 70 mg BID, as evidenced by comparable rates of
MMR (46 and 46%, respectively), PFS (42 and 44%, respectively), and
OS (65 and 68%, respectively). Deaths were most commonly disease-
related.
According to current European LeukemiaNet (ELN) recommenda-
tions, achievement of BCR–ABL1 (IS) 10% at 3 months defines
treatment response, predictive of long-term benefit and outcomes for
first-line therapy [9,15]. At 7 years, landmark analyses continue to
demonstrate that achieving early responses at 3 and 6 months trans-
lates to long-term clinical benefit with superior PFS and OS, consist-
ent with our previous study findings [1]. Seven-year OS rates for
patients with BCR–ABL1 (IS) 10% at 3 and 6 months were 72 and
74%, respectively, and the 7-year PFS rates for patients with BCR–
ABL1 (IS) 10% were 56 and 57% at 3 and 6 months, respectively.
Dasatinib was well tolerated, and no new safety signals were
detected in this analysis. The majority of AEs, both nonhematologic
and hematologic, occurred early in the course of treatment. Cumula-
tive rates of pleural effusion increased gradually over time in the
study population, including the 100 mg QD arm; however, with a
minimum follow-up of 7 years, incidence of drug-related pleural effu-
sion was less common in the 100 mg QD arm relative to other
TABLE II. Drug-Related Adverse Events of Interest Over Time
Treated patients, n/at risk (%)
100 mg QD (n 5 165) Other dose groups (n 5 497)
2-year 5-year 7-year 2-year 5-year 7-year
Pleural effusion 23/121 (14) 40/55 (24) 46/42 (28) 118/309 (24) 158/127 (32) 174/91 (35)
Pulmonary hypertension 0 (0) 0 (0) 3 (2) 5 (1) 8 (2) 13 (3)
Pulmonary arterial hypertension – 0 (0) 1 (<1) – 0 (0) 0 (0)
Number of patients at risk 5 number of patients treated within a given year not having that adverse event.
QD, once daily.
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treatment arms. Cumulative rates of PAH (and PH) remained low
throughout the duration of this study, at 0 to <1% (pH: 0–3%). We
recognize that PAH may not have been fully investigated, as to do so
would have required catheterizing patients, a procedure which was
performed in only a small number of patients.
As cardiac AEs have been identified with use of some BCR–ABL1
TKIs in CML [16–18], we evaluated their incidence with dasatinib.
Across all doses, arterial ischemic events occurred at low frequencies
(4%). Most cardiovascular ischemic events occurred during the first
year of treatment. Moreover, no increase in cardiovascular ischemic
events over time was observed. Likewise, peripheral vascular events
occurred in <1% across all dose groups, and no peripheral vascular
event occurred in the 100 mg QD dose group. Cerebrovascular events
were observed in 3% of patients, and there were no reports of stroke.
During this 7-year period, infections due to any cause occurred in
66% of patients. The most common types of infection were upper
respiratory infections, nasopharyngitis, and pneumonia. Most infec-
tions were grades 1/2. All infections were captured during the treat-
ment period, regardless of relationship to study treatment. Only a
minority of infections (17%) was deemed drug-related, and the
majority of infections resolved.
In this study, progression was defined as increasing WBC, loss of
CHR or MCyR, 30% increase in Ph1 metaphases, or transformation
to AP or BP disease. This definition differs from the current ELN and
National Comprehensive Cancer Network definitions of progression
[9,18,19]. Although patients were followed for OS on study discontinu-
ation, they were not followed for study-defined disease progression
after discontinuation. Additionally, in patients for whom progression
was reported, the reason of progression in the follow-up period was
not captured. Thus, we were not able to analyze PFS according to
intent-to-treat principles as per the ELN definition of progression
[9,19]. The differences between this study design and definitions set
forth by consensus guidelines underscores the challenges in making
cross-study comparisons. It was not possible to assess the incidences of
AP and BP, because of termination of follow-up, according to study
protocol. Also, the availability of commercial dasatinib substantially
reduced the number of patients who continued the study.
It should be noted that many of the patients included in this trial
received early lines of treatment that were not TKIs, such as inter-
feron, chemotherapy, and even allogeneic stem cell transplants.
Therefore, the study population may not be representative of CML-
CP patients who received imatinib as frontline therapy, and then
switched to dasatinib once they became resistant or intolerant to ima-
tinib. It is then possible that data for dasatinib in CML-CP patients
pretreated with imatinib only are better than those reported here.
With a minimum follow-up of 7 years, study CA180-034 provides
the longest follow-up for safety and efficacy of any second-line sec-
ond-generation BCR–ABL1 TKI. Overall OS was 65%. Long-term fol-
low-up data presented here confirm the 6-month, 2-year, and 6-year
results [1,6,7] of a positive benefit/risk associated with long-term
dasatinib use at its approved dose of 100 mg QD in CML-CP patients
with resistance or intolerance to imatinib. Arterial ischemic events
occurred at low frequencies. As pleural effusion may occur for the
first time in dasatinib-treated patients even after years of treatment,
monitoring for these symptoms should continue.
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